it Medical Team www.itmedicalteam.pl 2024

Vol.15 No.1:245

# Unmasking the Ebola Virus Disease: Unraveling the Mystery

# **Carlo Derelitto**\*

Department of Microbiology, University of Bologna, Bologna BO, Italy

\*Corresponding author: Carlo Derelitto, Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, Rotterdam, the Netherlands; E-mail: derelitto@yahoo.com

Received date: Jan 04, 2024, Manuscript No. IPACM-24-14270; Editor assigned date: Jan 08, 2024, PreQC No. IPACM-24-14270 (PQ); Reviewed date: Jan 22, 2024, QC No. IPACM-24-14270; Revised date: Jan 29, 2024, Manuscript No. IPACM-24-14270 (R); Published date: Feb 05, 2024, 10.36648/1989-8436.24.15.1.245

Citation: Derelitto C (2024) Unmasking the Ebola Virus Disease: Unraveling the Mystery. Arch Clinic Microbio Vol:15 No:1:245

# Introduction

Ebola Virus Disease (EVD), a menacing and deadly viral illness, has captured the world's attention multiple times over the years. While it might not be making daily headlines, the threat of Ebola remains, lurking in the background, waiting for the next opportunity to wreak havoc. This article aims to explore the multifaceted nature of the Ebola virus, its history, transmission, symptoms, treatment and the lessons learned from previous outbreaks.

# Description

# The history of Ebola

The Ebola virus was first identified in 1976 when a mysterious outbreak occurred in the Democratic Republic of Congo (then known as Zaire) and Sudan. The virus got its name from the Ebola River, near the location of the outbreak in Zaire. The virus belongs to the Filoviridae family and is primarily transmitted to humans from wild animals.

## Transmission

Understanding how the Ebola virus spreads is crucial in preventing its resurgence. The primary mode of transmission is through contact with the blood, secretions, organs, or other bodily fluids of infected animals, primarily fruit bats and monkeys, which serve as natural reservoirs. Once the virus makes the jump to humans, human to human transmission occurs through direct contact with the blood, secretions, organs, or other bodily fluids of infected individuals, as well as surfaces and materials contaminated with these fluids.

Ebola is notorious for its ability to spread rapidly within close knit communities, healthcare settings, and during burial rituals where mourners come into contact with the deceased. The virus can also be transmitted sexually and through breastfeeding, highlighting the need for comprehensive preventive measures to combat the disease.

### **Symptoms**

Ebola is a stealthy virus that incubates silently in the human body for 2 to 21 days after exposure. The initial symptoms are nonspecific, making it challenging to diagnose early on. These symptoms include fever, fatigue, muscle pain, headache and a sore throat. As the disease progresses, patients may experience vomiting, diarrhea, rash, impaired kidney and liver function and in some cases, internal and external bleeding.

The severity of symptoms can vary among individuals, with some succumbing to the disease within a matter of days and others fighting it off for weeks. The variability in symptoms adds to the complexity of managing EVD.

#### Treatment

There is currently no specific antiviral treatment for Ebola, making supportive care crucial for patients. This includes maintaining fluid and electrolyte balance, providing oxygen therapy and treating specific complications such as bleeding or bacterial infections. Early diagnosis and prompt treatment can significantly improve a patient's chances of survival.

#### **Preventive measures**

Preventing the spread of Ebola is of paramount importance, both in affected regions and globally. Public health measures such as isolating infected individuals, tracing and monitoring contacts and implementing rigorous infection prevention and control practices in healthcare settings are essential. The development of vaccines has also played a significant role in preventing the disease.

The rVSV-ZEBOV-GP vaccine, developed in the wake of the 2014-2016 West Africa outbreaks, showed promise in clinical trials and was used in subsequent outbreaks. It's worth noting that rapid deployment of vaccines during outbreaks is a testament to the global community's commitment to combating EVD.

#### Lessons from previous outbreaks

The history of Ebola outbreaks has provided invaluable lessons for the global community. Here are a few key takeaways:

**Strengthening healthcare systems:** Many countries with limited healthcare infrastructure struggled to contain Ebola outbreaks. Building robust healthcare systems, complete with trained healthcare workers, proper facilities and essential equipment, is essential for early detection and response.

Vol.15 No.1:245

**Early detection and rapid response:** The importance of early detection and swift, well-coordinated responses cannot be overstated. Timely diagnosis, contact tracing, and isolation of infected individuals are pivotal in preventing large scale outbreaks.

**Global collaboration:** Ebola outbreaks have demonstrated the need for international cooperation and solidarity. Global health organizations, governments and non-governmental organizations must work together to provide financial and logistical support to affected regions.

**Vaccine development:** The development and deployment of vaccines have been game-changers in the fight against Ebola. Ongoing research into additional treatments and vaccines is crucial to enhancing our ability to combat the disease.

**Community engagement:** Building trust and collaboration within affected communities is essential. Community leaders, local healthcare workers and international responders must work together to implement effective prevention and treatment strategies.

### **Challenges and controversies**

The battle against Ebola has not been without its challenges and controversies. Here are a few key issues:

**Ethical considerations:** The use of experimental treatments and vaccines during outbreaks has raised ethical questions.

Balancing the need to save lives with the need for rigorous clinical trials and informed consent remains a complex issue.

**Community resistance:** In some regions, distrust of healthcare workers and resistance to vaccination efforts have hindered containment. Building trust within affected communities is a persistent challenge.

**Funding gaps:** Sustained funding for research, preparedness, and response remains a challenge. Economic constraints, competing health priorities and donor fatigue can affect the resources available to combat EVD.

**Regional conflict and instability:** Ongoing conflicts in affected regions, such as the Democratic Republic of Congo, have created challenging environments for response efforts. Security concerns can impede the work of healthcare providers and responders.

# Conclusion

Ebola virus disease is a formidable adversary, capable of causing widespread devastation and posing an ongoing global threat. The history of Ebola outbreaks has taught us the importance of strong healthcare systems, early detection and response, global collaboration and community engagement. Advances in science and research have provided us with improved diagnostic tools, vaccines and potential treatments.